Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8816046
Compositions and methods for CaMKII inhibitors and uses thereof
granted -
US 8815885
Methods and compositions for modulating IRE1, SRC, and ABL activity
granted -
US 8808710
Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
granted -
US 8809268
Combination therapy to combat helminth resistance
granted -
US 8809377
Deubiquitinase inhibitors and methods for use of the same
granted -
US 8809016
Nucleic acids encoding modified vitamin K-dependent polypeptides
granted -
US 8809323
Therapeutic applications of pro-apoptotic benzodiazepines
granted -
US 8809291
Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma
granted -
US 8808715
Methods and compositions for modulating keratinocyte function
granted -
US 8808698
Methods for inhibition of lymphangiogenesis and tumor metastasis
granted -
US 8802633
Autophagy-inducing peptide analogs
granted -
US 8802733
Aldehyde dehydrogenase inhibitors as novel depigmenting agents
granted -
US 8802689
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
granted -
US 8802656
Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same
granted -
US 8802074
Polymers functionalized with ion-specific recognition elements
granted -
US 8796438
Nucleic acids encoding inactive variants of human telomerase
granted -
US 8796332
Compositions and methods for controlling infections
granted -
US 8795738
Use of arsenic for cancer therapy protection
granted -
US 8795650
Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
granted -
US 8796233
Methods and systems for modulating hormones and related methods, agents and compositions
granted -
US 8796008
Influenza A virus vaccines and inhibitors
granted -
US 8796209
Compositions and methods related to anti-FGF agents
granted -
US 8796223
Methods of inhibiting photoreceptor apoptosis
granted -
US 8795668
Methods for treating pulmonary fibrosis
granted -
US 8795661
Molecules with extended half-lives, compositions and uses thereof
granted -
US 8795656
Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody
granted -
US 8790631
Use of biocompatible polymers for the preparation of a composition or a medical device
granted -
US 8791149
Methods of treating traumatic brain injury using pro-neurogenic compounds
granted -
US 8791092
Molecular tweezers for the treatment of amyloid-related diseases
granted -
US 8790882
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
granted -
US 8791062
Skin permeating and cell entering (SPACE) peptides and methods of use thereof
granted -
US 8790655
Conjugates of synthetic TLR agonists and uses therefor
granted -
US 8790626
Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore
granted -
US 8791104
1,4-benzodiazepine-2,5-diones with therapeutic properties
granted -
US 8790878
Diagnosis and treatment of breast cancer
granted -
US 8784870
Controlled release compositions for modulating free-radical induced damage and methods of use thereof
granted -
US 8785409
Compounds having anti-adhesive effects on cancer cells
granted -
US 8785499
Targeting NAD biosynthesis in bacterial pathogens
granted -
US 8785514
Dual-cure dental resins and adhesives with increased cure and color stability and low color
granted -
US 8784866
Water-soluble carbon nanotube compositions for drug delivery and medicinal applications
granted -
US 8785505
Toxicology and cellular effect of manufactured nanomaterials
granted -
US 8785483
Methods for treating COPD
granted -
US 8785442
Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
granted -
US 8784881
Liposomal curcumin for treatment of diseases
granted -
US 8779094
Low viscosity highly concentrated suspensions
granted -
US 8781750
Cell-type-specific patterns of gene expression
granted -
US 8779151
Orally bioavailable caffeic acid related anticancer drugs
granted -
US 8781559
Method of evaluating metabolism of the eye
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory